Mergers & Acquisitions ·
Vivos agrees to acquire 11% stake in SOD Sciences and 50% of pseudohypoxia test for $12M preferred stock
VVOSVivos Therapeutics, Inc.
Vivos Therapeutics entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences to acquire an 11% fully diluted equity interest in SOD and a 50% co-ownership interest in its proprietary pseudohypoxia early-warning test. In exchange, Vivos will issue 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. The transaction involves no cash consideration and is expected to close on October 15, 2026, subject to customary conditions including auditor concurrence and Nasdaq notification. Vivos intends the preferred stock to be classified in permanent equity to help regain compliance with Nasdaq’s minimum stockholders’ equity requirement of $2.5 million. The deal opens potential collaboration opportunities through SOD’s relationships with Cleveland Clinic Weston and American Health Associates. Vivos Therapeutics is a medical technology company focused on developing diagnostic and treatment methods for obstructive sleep apnea.